PT  - JOURNAL ARTICLE
AU  - Singh, Harvineet
AU  - Mhasawade, Vishwali
AU  - Chunara, Rumi
TI  - Generalizability Challenges of Mortality Risk Prediction Models: A Retrospective Analysis on a Multi-center Database
AID  - 10.1101/2021.07.14.21260493
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.14.21260493
4099  - http://medrxiv.org/content/early/2021/12/01/2021.07.14.21260493.short
4100  - http://medrxiv.org/content/early/2021/12/01/2021.07.14.21260493.full
AB  - Modern predictive models require large amounts of data for training and evaluation, absence of which may result in models that are specific to certain locations, populations in them and clinical practices. Yet, best practices for clinical risk prediction models have not yet considered such challenges to generalizability. Here we ask whether population- and group-level performance of mortality prediction models vary significantly when applied to hospitals or geographies different from the ones in which they are developed. Further, what characteristics of the datasets explain the performance variation? In this multi-center cross-sectional study, we analyzed electronic health records from 179 hospitals across the US with 70,126 hospitalizations from 2014 to 2015. Generalization gap, defined as difference between model performance metrics across hospitals, is computed for area under the receiver operating characteristic curve (AUC) and calibration slope. To assess model performance by the race variable, we report differences in false negative rates across groups. Data were also analyzed using a causal discovery algorithm “Fast Causal Inference” that infers paths of causal influence while identifying potential influences associated with unmeasured variables. When transferring models across hospitals, AUC at the test hospital ranged from 0.777 to 0.832 (1st-3rd quartile or IQR; median 0.801); calibration slope from 0.725 to 0.983 (IQR; median 0.853); and disparity in false negative rates from 0.046 to 0.168 (IQR; median 0.092). Distribution of all variable types (demography, vitals, and labs) differed significantly across hospitals and regions. The race variable also mediated differences in the relationship between clinical variables and mortality, by hospital/region. In conclusion, group-level performance should be assessed during generalizability checks to identify potential harms to the groups. Moreover, for developing methods to improve model performance in new environments, a better understanding and documentation of provenance of data and health processes are needed to identify and mitigate sources of variation.Author Summary With the growing use of predictive models in clinical care, it is imperative to assess failure modes of predictive models across regions and different populations. In this retrospective cross-sectional study based on a multi-center critical care database, we find that mortality risk prediction models developed in one hospital or geographic region exhibited lack of generalizability to different hospitals or regions. Moreover, distribution of clinical (vitals, labs and surgery) variables significantly varied across hospitals and regions. Based on a causal discovery analysis, we postulate that lack of generalizability results from dataset shifts in race and clinical variables across hospitals or regions. Further, we find that the race variable commonly mediated changes in clinical variable shifts. Findings demonstrate evidence that predictive models can exhibit disparities in performance across racial groups even while performing well in terms of average population-wide metrics. Therefore, assessment of sub-group-level performance should be recommended as part of model evaluation guidelines. Beyond algorithmic fairness metrics, an understanding of data generating processes for sub-groups is needed to identify and mitigate sources of variation, and to decide whether to use a risk prediction model in new environments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the National Science Foundation grant number 1845487.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study performs secondary analyses of publicly available de-identified data, and thus is exempt from IRB approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available from the PhysioNet website and is accessible after completing a training course. https://eicu-crd.mit.edu/gettingstarted/access/ https://github.com/ChunaraLab/medshifts